On June 25, 2018, the Company announced to its employees the planned closing of its Pawtucket, RI manufacturing facility effective August 31, 2018. This is in line with the Company’s ongoing efforts to consolidate its manufacturing plants and streamline its existing processes. The manufacture of products previously produced in the Pawtucket, RI facility was substantially moved to Company facilities in Oxford, MA and Lenoir, NC during a two-month transition period. The Company completed the sale of its Pawtucket, RI location to a third-party in April 2020, for net proceeds totaling $1,810,000. This transaction resulted in a gain of $760,000 which was recorded during the third quarter of fiscal 2020. Also, during the third quarter of fiscal 2020, the Company recognized $85,000 in final Pawtucket, RI transition and exit costs, with no further costs related to this initiative anticipated in future periods.
Acquisition-Related Costs
In the second quarter of fiscal 2021, the Company incurred $128,000 of costs related to our February 5, 2021 acquisition of Emerging Technologies, Inc (“ETi”). This acquisition was accounted for as a business combination in accordance with applicable accounting standards, and all related professional service fees (including legal, accounting and actuarial fees) were expensed as incurred within the second fiscal quarter of 2021.
In the three- and nine-month periods ended May 31, 2020, the Company incurred $20,000 and $153,000 of costs related to our September 1, 2020 acquisition of ABchimie, respectively. This acquisition was accounted for as a business combination in accordance with applicable accounting standards, and all related professional service fees (including banking, legal, accounting and actuarial fees) were expensed as incurred within the second, third and fourth quarters of fiscal 2020 (total of $274,000 in acquisition-related expense recognized over the last three quarters of fiscal 2020). The transaction was consummated at the beginning of fiscal 2021.
Gain on Sale of Real Estate
In April 2020, the Company finalized the sale of its Pawtucket, RI location for net proceeds of $1,810,000. This transaction resulted in a gain of $760,000 which was recorded during the quarter ended May 31, 2020.
Loss (Gain) on Contingent Consideration
As a component of the September 1, 2020 acquisition of ABchimie, the Company incurred a performance-based earn out liability potentially worth an additional €7,000,000 (approximately $8,330,000 at the time of the transaction) in consideration. Following its initial recording at the acquisition date, $262,000 and $995,000 in expense related to adjustments to the performance-based earn out accrual were recorded for the three and nine months ended May 31, 2021, respectively.
Interest Expense
Interest expense increased $1,000 or 1% to $68,000 for the quarter ended May 31, 2021 compared to $67,000 in the prior year third quarter. Interest expense increased $26,000 or 15% to $204,000 for the first nine months of fiscal 2021 compared to $178,000 in the prior year period. As the Company had no outstanding balance on its revolving debt facility for both periods, interest expense has remained relatively low.
Other Income (Expense)
Other income (expense) was an expense of $260,000 in the quarter ended May 31, 2021, compared to an expense of $307,000 in the same period in the prior year, a decrease of $47,000. Other income (expense) was an expense of $758,000 in the nine months ended May 31, 2021, compared to an expense of $1,096,000 in the comparable period in the prior year, a decrease of $338,000. Other income (expense) primarily includes foreign exchange gains (losses) caused by changes in exchange rates on transactions or balances denominated in currencies other than the functional currency of the Company’s subsidiaries, non-service cost components of periodic pension expense (including pension-related settlement costs due to the timing of lump-sum distributions), interest income, rental income and other receipts that are not classified as trade, royalties or commissions.